Priorities for Ebola virus disease response in west Africa

The Lancet

Volumn 384, Issue 9957, 2014, Pages 1843-

  Jacob, Shevin T ^a   Crozier, Ian ^b   Schieffelin, John S ^c   Colebunders, Robert ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Accordia Global Health Foundation   (United States)

^c TULANE UNIVERSITY   (United States)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE;

AFRICA; CONVALESCENCE; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; EXPERIMENTAL THERAPY; HEALTH CARE PERSONNEL; HUMAN; LETTER; PLASMA TRANSFUSION; PRIORITY JOURNAL; SURVIVOR; DISEASE OUTBREAKS; ETHICS; FEMALE; HEMORRHAGIC FEVER, EBOLA; MALE;

DISEASE OUTBREAKS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; THERAPIES, INVESTIGATIONAL;

EID: 84924956168     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61609-3     Document Type: Letter

References (4)

1. Rid A, Emanuel EJ. Ethical considerations of experimental interventions in the Ebola outbreak. Lancet 2014; published online Aug. 22. http://dx.doi.org/10.1016/S0140-6736 (14) 61315-5.
2. Krech R, Kieny MP. The 2014 Ebola outbreak: ethical use of unregistered interventions. Bull World Health Organ 2014;92:622.
3. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; published online Aug. 29. DOI:10.1038/nature13777.
4. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999;179:S18-23.